Overview

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Status:
Recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

This study is a single center cohort study to access the anti-tumor efficacy, safety and tolerability of DZD9008 in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations and EGFR uncommon mutations who have progressed following standard TKI therapy, and in treatment naive patients with NSCLC harboring EGFR Exon20 insertion mutation.

Phase:

N/A

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborator:

Dizal (Jiangsu) Pharmaceutical Co., Ltd.